FOXO4-DRI is an experimental injectable peptide meant to destroy worn-out "senescent" cells by freeing the protein p53. In aged mice, courses restored fitness, regrew fur, and improved kidney function. The evidence is entirely from animals and cells; there are no human trials, no established dose, and its safety in people is unknown. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | < 1.0 mg/L | Tracks systemic inflammation linked to senescent-cell burden |
| IL-6 | Low end of assay reference (typically < 1.8 pg/mL) | A core SASP inflammatory signal senolytics aim to reduce |
| eGFR | > 90 mL/min/1.73 m² | Renal function was a key endpoint improved in animal studies; also a safety measure |
| Fasting glucose | 70–90 mg/dL | Metabolic health context for inflammation and aging |
| Complete blood count | Within age- and sex-adjusted normal ranges | Safety surveillance for any hematologic or infection-related change after injection |
Cadence: At baseline, at the end of a roughly three-week course, then every 3–6 months if courses are repeated.